ANTITUMOR THERAPY WIH ANTITRANSFERRIN RECEPTOR MONOCLONAL ANTIBODIES

使用抗转铁蛋白受体单克隆抗体的抗肿瘤治疗

• 批准号: 6102191
• 负责人: IAN S TROWBRIDGE
• 金额: --
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6102191
• 关键词: antireceptor antibody; basolateral membrane; biological transport; blood brain barrier; cell sorting; chimeric proteins; cooperative study; drug delivery systems; intracellular transport; laboratory mouse; laboratory rat; mutant; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer therapy; protein transport; tissue /cell culture; transcytosis; transferrin receptor; vascular endothelium

Monoclonal antibodies (mAbs) against the human transferrin (Tf) receptor have several potential applications in the treatment of cancer. This NCDDG program has previously developed antibodies against the human Tf receptor that directly block receptor function and inhibit cell proliferation as anti-tumor agents. It is now proposed to investigate the use of anti-Tf receptor mAbs to deliver anti-cancer agents across the blood-brain barrier. Targeting of anti-Tf receptor mAbs to Tf receptors selectively expressed on brain capillary endothelial cells and the delivery of covalently-coupled drugs and growth factors to the brain by anti-Tf receptor mAbs has been demonstrated by other investigators. The lack of an in vitro cell model to study Tf receptor trafficking in brain capillary endothelial cells, however, has limited quantitative studies of this process and analysis of the molecular mechanism involved. In preliminary studies supported by this NCDDG program, an in vitro brain endothelial cell culture model has now been established. The specific aims of the current proposal are to use this in vitro cell culture model to characterize Tf receptor trafficking pathways in brain capillary endothelial cells; to define the molecular sorting signals involved; to optimize transcytosis of anti-Tf receptor mAbs across brain capillary endothelial cells; and to identify candidate anti-Tf receptor mAbs for preclinical trials of drug targeting via the Tf receptor in an in vivo model. The longterm goal is to develop more effective methods of treating brain malignancies by developing effective receptor-mediated delivery of anti-tumor agents to the brain. This goal will be achieved by employing existing molecular cell biological, biochemical and morphological techniques previously applied to analyze Tf receptor trafficking in other cell typed As a specific model for delivery of biologically-active fusion proteins across the blood brain barrier, the ability of a anti-human Tf receptor/IL-2 fusion protein, constructed as described in program II of this NCDDG to be targeted from the apical surface to the basolateral surface of brain capillary endothelial cells will be investigated. Interaction with other program leaders in this NCDDG and with NCI staff will continue to facilitate the transition of laboratory work performed in this program to the clinic.

针对人转铁蛋白（TF）受体的单克隆抗体（mAb） 在癌症治疗中有几种潜在的应用。这个NCDDG 程序以前已经开发了针对人TF受体的抗体 直接阻断受体功能并抑制细胞增殖 抗肿瘤剂。现在建议研究抗TF的使用 受体mabs以在血脑内输送抗癌剂 障碍。选择性地靶向TF受体的抗TF受体mAB 在脑毛细管内皮细胞上表达 通过抗TF共价耦合的药物和生长因子 其他研究人员已经证明了受体mAB。缺乏 体外细胞模型研究脑毛细管中TF受体运输 但是，内皮细胞对此有限的定量研究有限 涉及分子机制的过程和分析。 在该NCDDG计划支持的初步研究中，体外大脑 现已建立内皮细胞培养模型。具体目标 当前的建议是将此体外细胞培养模型用于 表征脑毛细管中TF受体运输途径 内皮细胞；定义涉及的分子分选信号；到 优化跨脑毛细管的抗TF受体mAb的转胞膜 内皮细胞；并确定候选抗TF受体mAB 通过体内TF受体的药物靶向临床前试验 模型。长期目标是开发更有效的治疗方法 大脑恶性肿瘤通过开发有效的受体介导的输送 大脑的抗肿瘤剂。这个目标将通过采用 现有的分子细胞生物学，生化和形态学 以前用于分析其他TF受体运输的技术 细胞作为用于递送生物活性融合的特定模型 蛋白质穿过血脑屏障，抗人TF的能力 受体/IL-2融合蛋白，如计划II中所述构建 此NCDDG是从顶部表面到基底外侧的 将研究脑毛细管内皮细胞的表面。 与此NCDDG和NCI员工的其他计划负责人的互动 将继续促进实验室工作的过渡 该计划前往诊所。